Covid: Fiocruz and Sabin test the effectiveness of fractional dose booster
Fundação Oswaldo Cruz do Mato Grosso do Sul (Fiocruz) and Instituto Sabin de Vacinas started a study to evaluate the possibility of splitting booster doses of vaccines against Covid-19.
The researchers want to understand whether lower doses can offer the same immune response to the body, with fewer adverse reactions.
Positive results would enable a greater supply of vaccines to the population, facilitating access in low- and middle-income countries.
Copy of 3 Cards_Gallery_of_Photos (14)
Faced with the pandemic scenario and the expansion of the booster dose, some people still wonder what is the importance of the third dose of the vaccine against Covid-19stock
***Children’s vaccination against Covid-19
The booster dose should be administered at least four months after the individual completes the initial vaccination schedule. The extra application serves to increase the number of memory cells and further strengthen the antibodies they produce.Rafaela Felicciano / Metropolis
***Vaccination against Influenza Influenza
Specialists point out that one of the main measures provided by the booster dose is the expansion of the immune response. The third dose causes an increase in the amount of antibodies circulating in the body, which reduces the chance of the immunized person getting sick.Tomaz Silva/Agência Brasil
***DF begins to immunize 12-year-olds and reinforces vaccine for 80-year-olds
For the elderly and immunosuppressed, the booster dose increases the effectiveness of immunization, since these groups do not develop an adequate immune response.Hugo Barreto / Metropolis
Another important measure is to reduce the chance of infection in case of new variants. The antibody promoted by the vaccine is directed to the strain that gave rise to the formula and, in this process, people also produce antibodies that have diversity. The greater the reach of the proteins that defend the organism, the greater the probability that some will bind to the new variant.Westend61/GettyImages
*** Vaccine against covid _ Coronavac _ butantan
The director of the Brazilian Society of Immunizations (SBIm) and member of the Technical Advisory Committee of the National Immunization Program of the Ministry of Health, Renato Kfouri states that the scheme of mixing vaccines from different laboratories is a Rafaela Felicciano / Metropolis
***covid vaccine Increase in the number of covid-19 and Influenza cases in Brazil 6
A study conducted by the University Hospital Southampton NHS Foundation Trust in the UK showed that people who received two doses of AstraZeneca had a 30-fold increase in antibody levels after the Moderna vaccine booster, and a 25-fold increase with the booster of the vaccine. pfizerArthur Menescal/Special Metropolis
***Ticuna village _ indigenous people are vaccinated against covid-19 in the amazon
Reactions to the booster dose are similar to the two previous doses. Mild to moderate symptoms such as excessive tiredness and pain at the injection site are expected to occur. However, there are also reports of symptoms that include local redness or swelling, headache, muscle pain, chills, fever or nausea.Rafaela Felicciano / Metropolis
***With low demand, vaccination against H1N1 in Goiânia focuses on i
It is worth noting that the use of three doses has the main objective of reducing the number of serious cases and the number of hospitalizations for Covid-19.Vinícius Schmidt/Metropolis
The study will be carried out with 1,440 Brazilian volunteers who have not yet taken booster doses. They will be followed up for six months after receiving vaccines from Pfizer – full, half or one third dose –, AstraZeneca – full or half dose – or Coronavac – full dose.
During this period the researchers will make four visits within 28 days after the application of the immunizer, three months and six months to collect blood samples from the participants.
“With the pandemic, there was great pressure for an immunizing agent that was effective. We were in a situation where we couldn’t risk failing. But we’re at a point now where we have the opportunity to optimize that dose,” said Vice President of Applied Epidemiology at the Sabin Vaccine Institute, Denise Garrett.